Molnupiravir: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 30: | Line 30: | ||
[[Category:COVID-19]] | [[Category:COVID-19]] | ||
[[Category:Antiviral drugs]] | [[Category:Antiviral drugs]] | ||
==Molnupiravir== | |||
<gallery> | |||
File:MK-4482.svg|Molnupiravir chemical structure | |||
File:Molnupiravir metabolism.svg|Molnupiravir metabolism | |||
File:Molnupiravir GC bonding.svg|Molnupiravir GC bonding | |||
File:Molnupiravir AU bonding.svg|Molnupiravir AU bonding | |||
File:Molnupiravir synthesis.svg|Molnupiravir synthesis | |||
</gallery> | |||
Revision as of 01:13, 20 February 2025
Molnupiravir is an antiviral drug that is currently under investigation for its potential use in the treatment of COVID-19. It was developed by the pharmaceutical companies Merck and Ridgeback Biotherapeutics.
History
Molnupiravir was initially developed for the treatment of influenza. It was discovered by scientists at Emory University and is based on the compound N4-hydroxycytidine. The drug works by introducing errors into the RNA of the virus, which prevents the virus from replicating.
Clinical Trials
In 2020, Molnupiravir entered Phase II clinical trials for the treatment of COVID-19. Preliminary results from these trials have shown that the drug may reduce the duration of infectiousness for individuals with COVID-19.
Mechanism of Action
Molnupiravir works by introducing errors into the RNA of the virus, which prevents the virus from replicating. This is achieved through the drug's active metabolite, EIDD-2801, which is incorporated into the virus's RNA.
Potential Side Effects
As with any drug, Molnupiravir may have potential side effects. These can include nausea, diarrhea, and headache. However, these side effects are generally mild and temporary.
